



iOS event app



Android event app

Event apps will be live from 14 January 2026

# PVRI 2026 Dublin Annual Congress

28 January - 1 February 2026

A photograph of several people at a conference. In the foreground, a man with glasses and a grey suit is smiling and pointing towards the right. Behind him, other people are visible, including a man in a dark shirt and a woman with blonde hair. The background is slightly blurred, showing an outdoor setting with greenery.

## Celebrating 20 Years of Progress & Innovation

Dublin Royal Convention Centre, One Le Pole Square, Ship Street Great, Dublin, D08 E6PD

# Celebrating 20 years of PVRI

As we prepare to gather for the PVRI 2026 annual Congress, we also prepare to mark a milestone of great significance: the 20th anniversary of the Pulmonary Vascular Research Institute. For two decades, PVRI has stood as a global network advancing research, education, and collaboration in pulmonary hypertension (PH). This anniversary is both a celebration of achievement and a reminder of the important work ahead.

## A global mission from the start

Founded in 2006, PVRI emerged from a shared recognition that addressing PH needed a more coordinated, international approach. At the time, understanding was limited, therapeutic options were scarce, and the voices of patients were too often absent from the global health agenda. PVRI was created to change this - by connecting clinicians, scientists, industry partners, and patient advocates across continents, and by building a framework for knowledge exchange that transcended borders.



*PVRI inaugural meeting, London, 2006*

From its very first meeting, PVRI placed inclusivity at the heart of its mission. Meetings became not only scientific forums but also vibrant spaces where ideas could be tested, collaborations launched, and young investigators encouraged. This spirit of openness and dialogue continues to be the hallmark of our community.

## Scientific progress & global collaboration

Over the past 20 years, the field of pulmonary vascular medicine has changed dramatically. We have witnessed the development of new therapies, advances in imaging and biomarkers, and breakthroughs in genetics, molecular biology, and epidemiology. PVRI has played a key role in supporting and disseminating this progress.

Our Task Forces and IDDI Workstreams have helped to identify research priorities, harmonise definitions, and expand access to knowledge in regions where resources are limited. From guidelines that shape clinical practice to collaborations that cross disciplines and borders, PVRI has been instrumental in ensuring that progress in science translates into progress for patients everywhere.

## Nurturing the next generation

Equally important has been PVRI's commitment to education and mentorship. Over the past two decades, hundreds of early-career researchers and clinicians have been supported through travel grants and opportunities to present their work. Many of today's leaders in the field began their journey as young investigators supported by PVRI. This investment in people has strengthened our network and ensured a vibrant pipeline of talent. As we look to the future, we remain committed to inspiring and equipping the next generation.

## A truly international community

PVRI has also distinguished itself by embracing a truly global perspective. PH affects people everywhere, yet its burden is particularly severe in regions with limited access to healthcare. Recognising this, PVRI has sought to amplify the voices of colleagues in low- and middle-income countries, integrating their experiences and expertise into our collective work. By bringing together perspectives from every corner of the globe, PVRI has fostered an international community united by a shared purpose.

## Looking ahead: the next 20 years

As we celebrate our 20th anniversary, we are proud of how far we have come. But we are also mindful of how much there is still to do. PH remains a life-limiting condition for many, and disparities in diagnosis, treatment, and research resources persist worldwide. PVRI enters its third decade with renewed determination: to push the boundaries of science, to drive innovation in therapies and care models, and to continue advocating for patients everywhere.

## A community of hope

Ultimately, PVRI is more than an organisation - it is a community. For 20 years, we have been bound together by a shared commitment to improve the lives of patients and families affected by PH. As we look ahead, this mission will continue to guide and inspire us.

To everyone who has been part of the PVRI journey - members, partners, supporters, and patients - we extend our heartfelt thanks and we can't wait to celebrate with you at PVRI 2026.



*Miami, 2017*

# Thank you to our PVRI 2026 Scientific Organising Committee

We are truly grateful to all the members of the PVRI 2026 Scientific Organising Committee (SOC) led by Seán Gaine. The success of our annual Congress depends on their dedication, vision, and expertise to shape an engaging and forward-looking scientific programme.

Their thoughtful selection of sessions and talks reflects not only the breadth of pulmonary vascular research today, but also the urgent need to address the challenges that remain in diagnosis, treatment, and global access to care. Thanks to their leadership, PVRI 2026 offers a truly international platform where established experts and early-career investigators alike can exchange ideas, foster collaborations, and inspire innovation.

This year's programme spans cutting-edge AI and precision medicine, the latest therapeutic strategies, and the future of living with PH. It not only showcases how far we've come, but also points to the possibilities ahead. In "Celebrating 20 Years of Progress & Innovation", we honour the achievements of our community and our shared drive to accelerate progress together.

We are particularly grateful for the committee's attention to mentoring and education. By creating space for young investigators and trainees, the SOC has reinforced the importance of nurturing the next generation of leaders in pulmonary hypertension. Their efforts to integrate networking time, poster discussions, and a career development session will leave a lasting impact well beyond this meeting.

On behalf of the PVRI Board, our members, and—most importantly—the patients who inspire our work, we offer heartfelt thanks to every member of the Scientific Organising Committee.

Your commitment, creativity, and passion have shaped PVRI 2026 into a landmark event that will advance science, strengthen collaboration, and build hope for the future.



**Anna Hemnes**  
PVRI President 2024-26



**Seán Gaine**  
Mater Misericordiae University Hospital

Seán is Consultant Respiratory Physician at Mater Misericordiae University Hospital in Dublin and

Director of the National PH Unit. Seán completed his medical education at Trinity College Dublin and his medical residency and Pulmonary and Critical Care fellowship training at the Johns Hopkins Hospital. He subsequently held faculty positions at the Johns Hopkins Hospital and at the University of Maryland School of Medicine. He established the PH Center at the Johns Hopkins Hospital and the National PH Unit upon his return to Dublin. Seán has been a working member of the ESC and ERS PH Guideline Committee in the past, and a Task Force member of the WHO World PH Symposiums. On a different note, Seán was Chief Medical Officer of the Olympic Council of Ireland and led the medical team at the Games in Athens, Beijing, London and Rio.



**Katarina Zeder**  
University of Maryland

Dr. Katarina Zeder, MD PhD, is a clinician scientist in the field of PH. Her research interests evolve

around early recognition of disease utilising exercise, characterisation of PH in COPD and CKD, PH epidemiology and artificial intelligence in PH. In these areas, Dr. Zeder has authored multiple high-impact publications including first-author publications at Nature Reviews, European Heart Journal and European Respiratory Journal, which brought her several abstract and publication prizes. Dr. Zeder started her research career at the Medical University of Graz and Ludwig Boltzmann Institute for Lung Vascular Research in Austria. Her research endeavours lead to research fellowships at Harvard Medical School and later at the University of Maryland, Institute for Health Computing and School of Medicine, Division of Respiratory Medicine, where she joined the faculty in 2025.

**Soni Savai Pullamsetti**

Justus Liebig University

Prof. Dr. Soni Savai Pullamsetti is a Professor at Justus Liebig University Giessen and a Principal

Investigator at the Max Planck Institute for Heart and Lung Research in Bad Nauheim, where she leads the research groups Lung Vascular Epigenetics and Molecular Mechanisms of Pulmonary Vascular Disease. A specialist in pulmonary hypertension and fibrosis, her work focuses on how epigenetic and transcriptional mechanisms drive chronic lung disease and inform novel therapeutic strategies. She also serves as Coordinator of the Disease Area at the German Center for Lung Research (DZL). In 2023, she was elected to the Leopoldina, Germany's National Academy of Sciences.

**Mark Toshner**

University of Cambridge

Dr. Mark Toshner is an Associate Professor in Translational Respiratory Medicine at the

University of Cambridge and an Honorary Consultant at Royal Papworth Hospital. He is Director of the Clinical Research Facility within the Victor Phillip Dahdaleh Heart & Lung Research Institute. A clinician-scientist focused on pulmonary vascular disease, he leads innovative experimental medicine studies and clinical trials, including the HEAL-COVID and StratosPHere platforms, and has been an advocate of adaptive, decentralised trial designs and researcher networks to advance therapy development.

**Catherine Simpson**

Johns Hopkins University

Dr. Catherine Simpson is an Assistant Professor of Medicine at Johns Hopkins University

School of Medicine and Associate Program Director of Research in Pulmonary and Critical Care Medicine. A specialist in internal medicine, pulmonary and critical care, and pulmonary vascular diseases, she holds an MD from Louisiana State University School of Medicine and an MHS from the Johns Hopkins Bloomberg School of Public Health. Dr. Simpson completed both her residency and fellowship at Johns Hopkins, and her clinical and research focus centres on pulmonary vascular disease.

**Shahin Moledina**

Great Ormond Street

Dr. Shahin Moledina is a Consultant Paediatric Cardiologist at Great Ormond Street Hospital for Children

and Director of the National Paediatric Pulmonary Hypertension Service for the UK and co-lead of the paediatric and congenital heart disease task force of the PVRI. Dr. Moledina is active in research including phenotyping, outcomes and clinical trials in PH. He has a particular interest in cross-sectional imaging, particularly cardiac MRI. His group hosts a national clinical and imaging registry with a linked biorepository.

**William Oldham**

Warren Alpert Medical School of Brown University

Dr. William Oldham is a pulmonologist and intensivist

at the Warren Alpert Medical School of Brown University. His research focuses on how cellular metabolism drives the lung diseases PH and pulmonary fibrosis. Utilising state-of-the-art analytical techniques – metabolomics, stable isotope tracing, extracellular flux analysis, and systems biology – his lab aims to transform our understanding of lung disease. By targeting the metabolic processes of cells, his team is working to develop innovative therapies that offer new hope for patients with these complex conditions.

**Jason Weatherald**

University of Alberta

Dr. Jason Weatherald is an Associate Professor at the University of Alberta, specialising

in PAH, CTEPH, group 3 PH, and lung transplantation. His research focuses on risk assessment and patient-centred studies in PH, exploring innovative clinical trial designs and endpoints. Since 2020, he has also contributed to COVID-19 research, particularly in awake-prone positioning and the long-term impacts of the COVID-19 pandemic on pulmonary diseases. Widely published, he is a recognised leader in pulmonary medicine, dedicated to improving patient care and advancing clinical practice.

# Programme overview

## Satellite meetings

### Wednesday, 28 January

08:00-14:30	Innovative Drug Development Initiative (IDDI), Robinson 1 + 2, 1st floor
08:00-11:45	Latin America Task Force, Higgins 2, 1st floor
08:00-12:00	Imaging Task Force, Higgins 1, 1st floor
13:00-18:00	Paediatric & Congenital Task Force, Higgins 1, 1st floor
13:00-18:00	Infection in Pulmonary Vascular Disease (iPVD) Consortium, Higgins 2, 1st floor
15:00-18:00	High Altitude Task Force, Robinson 1 + 2, 1st floor

## Scientific programme, Douglas Hyde, ground floor (unless otherwise stated)

### Thursday, 29 January: 20 years of progress in PAH

08:00-08:10	PVRI's President's welcome
08:10-09:40	Session 1: Sotatercept: from clinical trials to emerging insights
09:40-10:10	Refreshment break Breakout area, ground & 1st floor
10:10-12:05	Session 2: Translational insights into promising targets & pathways
12:05-13:50	Buffet lunch Breakout area, ground & 1st floor
12:45-13:45	The evolution of PH: tales from medical history
12:05-13:30	Women's Health Task Force 'meet & greet' - All welcome Phoenix Boardroom, 1st floor
13:50-15:45	Session 3: Two organs, one mission: the right ventricle-lung alliance
15:45-17:00	Poster Presentations with refreshments Robinson + Higgins, 1st floor
17:10-18:40	Networking Reception Breakout area, ground floor

### Friday, 30 January: 20 years advances in all-cause PH

08:00-09:55	Session 4: PH associated with lung diseases: hope or hype?
09:55-10:25	Refreshment break Breakout area, ground & 1st floor
10:25-11:55	Session 5: Global aspects of PH
11:55-13:40	Buffet lunch Breakout area, ground & 1st floor
11:55-13:40	Career Catalyst Luncheon (bookable) Radisson Blu Royal Hotel Dublin Restaurant
13:40-15:10	Session 6: 20 years of progress in CTEPH
15:10-16:15	Poster Presentations with refreshments Robinson + Higgins, 1st floor
16:15-17:45	Session 7: Translating innovation into PH therapies
19:30-00:30	Gala Dinner & Award Evening Guinness Storehouse

### Saturday, 31 January: The next 20 years of PH

08:00-09:55	Session 8: Precision medicine & artificial intelligence in PH
09:55-11:00	Poster Presentations with refreshments Breakout area, ground & 1st floor
11:00-12:00	Session 9: Sharks Den - new targets, biomarkers & devices in PH
12:00-13:45	Buffet lunch Breakout area, ground & 1st floor
12:00-13:45	Women in PH Luncheon Radisson Blu Royal Hotel Dublin Restaurant
13:45-15:00	Session 10: Innovative concepts for future thinking in PH
15:00-15:30	Refreshments break Breakout area, ground & 1st floor
15:30-16:30	Session 11: The future hope of living life to the full with PH
16:30-16:35	Meeting close

## Satellite meeting

### Sunday, 1 February

08:00-13:00	PAH-ICON: International Consortium for Genetic Studies in PAH, Robinson, 1st floor
-------------	--

## Latin America (LATAM) Task Force

08:00-08:15 Welcome from the LATAM Task Force  
Executive Committee

### Session 1

*Moderators:* Tomas Pulido & Nayeli Zayas

08:15-08:30 PH in LATAM: an update from the CAPRI Registry  
TBC

08:30-08:45 Findings of the Clarity Study relevant to CTEPH in LATAM  
TBC

08:45-09:00 The LATAM PE Registry  
Carlos Jerjes-Sánchez

09:00-09:15 Update on the diagnosis & treatment of paediatric PH in LATAM  
TBC

09:15-09:45 Discussion  
All

---

09:45-10:00 Refreshment break, Breakout area

---

### Session 2

*Moderators:* Carlos Jerjes & Mauricio Orozco

10:00-10:15 The Mexican guidelines for diagnosis & treatment of PH  
TBC

10:15-10:30 Exercise testing in the diagnosis & treatment of PH in LATAM  
TBC

10:30-10:45 PH in LATAM patients living in the USA  
TBC

10:45-11:00 PH clinical trials in LATAM  
TBC

11:00-11:15 Unmet needs in PH management in LATAM  
TBC

11:15-11:30 Discussion  
All

11:30-11:45 Closing remarks

ROOM: Higgins 2  
(1st floor)

## Imaging Task Force

ROOM: Higgins 1  
(1st floor)

Imaging in PH - building a consensus for the future: non-invasive imaging metrics in patients with suspected and confirmed PH

### Session 1

Moderators: TBC

- 08:00-08:20 Welcome & introduction  
TBC
- 08:20-08:40 My imaging journey - what I currently get from imaging & what I need  
TBC
- 08:40-09:00 Global challenges in imaging access  
TBC
- 09:00-09:30 Discussion  
All

---

09:30-09:45 Refreshment break, Breakout area

---

### Session 2: Individual imaging modalities

Moderators: TBC

- 09:45-10:00 CT imaging - what features should always be provided, & what additional features could be extracted?  
TBC
- 10:00-10:15 Where is CT imaging headed?  
TBC
- 10:15-10:30 Echocardiography - what features should always be provided, & what additional features could be extracted?  
TBC
- 10:30-10:45 Where is echocardiographic imaging headed?  
TBC
- 10:45-11:00 MR imaging - what features should always be provided, & what additional features could be extracted?  
TBC
- 11:00-11:15 Where is MR imaging headed? - 4D modelling  
TBC
- 11:15-11:30 Moderated discussion  
TBC

### Session 3: PVRI imaging statement 2.0

Moderators: TBC

- 11:30-11:50 Updating algorithm & imaging statement  
TBC
- 11:50-12:00 Session summary  
TBC

## Paediatric & Congenital Heart Disease Task Force

### Joint Paediatric & Congenital Heart Disease Task Force & IDDI Paediatric Workstream session

#### Breaking new collaborative ground in paediatric PH

*Moderators: Steven Abman, Maria Jesús del Cerro, Shahin Moledina, & Sylvia Nikkho*

- |             |   |
|-------------|---|
| 13:00-13:05 | Introduction & joint collaboration<br>Maria Jesús del Cerro   |
| 13:05-13:15 | Patients & families first: outcomes of the paediatric PHGPS survey<br>Maurice Beghetti (recording)    |
| 13:15-13:35 | Development of a new risk score for paediatric PH: collaborative registry studies<br>Megan Griffiths  |
| 13:35-13:50 | Enhancing paediatric drug development in PH: extrapolation from adult data<br>TBC                     |
| 13:50-14:05 | Innovative imaging endpoints in paediatric PH<br>Shahin Moledina                                      |
| 14:05-14:20 | Navigating the neonatal landscape: challenges & opportunities in drug development<br>Anne Hilgendorff |
| 14:20-14:30 | Closing remarks & next steps<br>Sylvia Nikkho   |

---

14:30-15:00 Refreshment break, Breakout area

---

### Paediatric & Congenital Heart Disease Task Force meeting

- |             |  |
|-------------|--|
| 15:00-15:05 | Welcome to the Paediatric Task Force meeting<br>Shahin Moledina, Steven Abman, Maria Jesús del Cerro |
|-------------|--|

#### Update on Paediatric & Congenital Heart Disease Task Force ongoing projects

*Moderators: Steven Abman & Marilyn Levy*

- |             |  |
|-------------|--|
| 15:05-15:15 | Panama Class update - results of survey<br>Nidhy Varghese & Rachel Hopper                      |
| 15:15-15:25 | Inclusion of paediatric patients in GoDeep Registry<br>Anne Hilgendorf & Megan Griffith        |
| 15:25-15:35 | Understanding the current paediatric PH landscape – scoping surveys project<br>Shahin Moledina |
| 15:35-15:45 | Discussion<br>All  |

#### I have a research project I want to share...

*Moderators: Shahin Moledina & Usha Raj*

- |             |  |
|-------------|--|
| 15:45-15:55 | Digital stethoscope & AI to detect PAH<br>Prashant Bobhate |
|-------------|--|

ROOM: Higgins 1  
(1st floor)

# Satellite meetings, 28 January

## Paediatric & Congenital Heart Disease Task Force

- 15:55-16:05      Endothelial dysfunction studies in an ovine Glenn Model  
TBC
- 16:05-16:15      Unveiling the uncommon: exploring rare genotypes & deep phenotyping in  
paediatric PH for enhanced registry insight  
Mary Mullen
- 16:15-16:30      Discussion  
All
- 16:30-16:40      Assessment of operability in shunts lesions with severe PH  
Anita Saxena
- 16:40-16:50      Research with IPCs from different genetic variants  
TBC
- 16:50-17:00      Research on critical care & support devices for paediatric PH  
Ryan Coleman
- 17:00-17:15      Discussion  
All
- I have a clinical case I want to discuss...**  
*Moderators: Rachel Hopper, Maria Jesús del Cerro, Taylor Saley*
- 17:15-17:25      Cases from Columbia University  
Humberto Garcia Aguilar
- 17:25-17:40      Cases from Columbia University  
TBC
- 17:40-17:50      Discussion  
All
- 17:50-18:00      Proposals for next year activities & closure  
Maria Jesús del Cerro, Steven Abman & Shahin Moledina



ROOM: Higgins 1  
(1st floor)

## High Altitude Task Force

ROOM: Robinson 1 + 2  
(1st floor)

**Moderators:** Max Gassmann

Each talk includes 10 minutes of discussion time

- 15:00-15:30     Metabolomic changes in high altitude  
Andrea Olschewski
- 15:30-16:00     Cardioprotective role of SMYD2 in right ventricular hypertrophy  
Ralph Schermuly
- 16:00-16:30     PH in children at high altitude - the importance of early detection &  
hyperreactivity of pulmonary vasculature  
Gabriel Fernando Diaz Gongora
- 16:30-17:00     What is the expected PAP increase in healthy people going to altitude or leaving  
at high altitude?  
Julian Müller
- 17:00-17:30     Supplemental oxygen therapy & relocation to low altitude in highlanders at risk for  
PH, & patients diagnosed with PAH at high altitude  
Silvia Ulrich
- 17:30-18:00     Discussion & future perspectives  
All attendees



## Infection in Pulmonary Vascular Disease (iPVD) Consortium Task Force

13:00-13:10	iPVD updates & recent developments Rudolf Oliveira
<b>Session 1:</b> <i>Moderators:</i>	<b>Challenges &amp; opportunities in conducting PAH clinical trials in LMIC</b> <i>Sharilyn Almodovar &amp; Michael Lee</i>
13:10-13:25	Highlights of the NIH Sch-PAH multicenter initiative Brian Graham
13:25-13:40	Advances in the clinical diagnosis Sch-PAH Camila Loureiro
13:40-13:55	Pathways to diagnose iPVDs in rural areas Ana Olga Mocumbi
13:55-14:10	ATS statement on PH diagnosis in LMIC Peter Nyasulu
14:10-14:30	Discussion All speakers
14:30-15:00	Refreshment break, Breakout area
<b>Session 2:</b> <i>Moderators:</i>	<b>Environmental stressors &amp; iPVD</b> <i>Suellen D'arc Oliveira &amp; Rudolf Oliveira</i>
15:00-15:15	The pulmonary vasculature at risk: pollution & PVD TBC
15:15-15:30	Extracellular vesicles, exposomes & HIV associated PH Navneet Dhillon
15:30-15:45	The sleep, infection & PH triad Andrew Bryant
15:45-16:00	N-Ras: a novel player in endothelial & T cell pathophysiology in PH? Edgar Fernández-Malavé
16:00-16:20	Discussion All speakers
<b>Session 3:</b> <i>Moderators:</i>	<b>New advances in the role of microbiome in PVD pathophysiology</b> <i>Angel Cogolludo &amp; Gerald Maarman</i>
16:20-16:35	Gut-lung crosstalk in Sch-PH Suellen D'arc Oliveira
16:35-16:50	Microbiome as a treatment option in PAH Thenappan Thenappan
16:50-17:05	The link between microbiome, infection & PVD Sharilyn Almodovar
17:05-17:20	Discussion All speakers
17:20-17:30	Closing remarks Rudolf Oliveira

ROOM: Higgins 2  
(1st floor)

# Scientific programme, 29 January

08:00–08:10 PVRI President's welcome  
Anna Hemnes

## SESSION 1: Sotatercept: from clinical trials to emerging insights

*Moderators:* David Badesch, Luke Howard & Shelsey Johnson

08:10–08:35 Sotatercept: from clinical trials to real world data & pearls from practice  
Ioana Preston

08:35–09:00 Vascular remodeling effects: how else does sotatercept work?  
Ardeschir Ghofrani

09:00–09:15 Sotatercept impairs right ventricular function: insights from multi-center preclinical studies  
Sarah-Eve Lemay

09:15–09:40 Beyond sotatercept, what is the future of TGF $\beta$ /activin signaling in PAH?  
Paul Yu

09:40–10:10 Refreshment break, Breakout area

## SESSION 2: Translational insights into promising targets & pathways

*Moderators:* Sebastien Bonnet & Navneet Singh, Silvia Ulrich

10:10–10:35 KEYNOTE: Mitochondrial & metabolic modulators for PH: opportunities & challenges  
Anna Hemnes

10:35–11:00 Is the basement membrane a novel therapeutic target in PAH?  
Grazyna Kwapiszewska

11:00–11:15 Platelet activation & macrophage recruitment drive vascular dysfunction in a murine model of sickle cell PH  
Daniel Colon Hidalgo

11:15–11:40 Is the lysosome the next big thing in PAH?  
Stephen Chan

11:40–12:05 Cellular senescence & PH: divergent roles & emerging targets  
Serge Adnot

12:05–13:50 Lunch break, Breakout area

12:45–13:45 The evolution of PH: tales from medical history  
*Moderators:* Ghazwan Butrous & Gregory Elliott

12:45–13:00 From nihilism to innovation: the evolution of PH treatment,  
Lewis Rubin

13:00–13:15 Stories of discovery: genetics of PVD, Richard Trembath

13:15–13:30 From Hamburg to Denver and to Sugen - a personal history of how lung vascular research developed, Norbert Voelkel

13:30–13:45 The power of "we": how team building transformed PVD research at Giessen & globally, Werner Seeger

12:05–13:30 Women's Health Task Force 'meet & greet', Phoenix Boardroom, 1st floor

**SESSION 3: Two organs, one mission: the RV-lung alliance**

*Moderators: Catherine Simpson, Karin Tran-Lundmark & Anton Vonk Noordegraaf*

13:50-14:15 The forgotten chamber: what can we learn from the right atrium in PH?  
Thenappan Thenappan

14:15-14:40 The misunderstood chamber: phenotyping the right ventricle  
Rebecca Vanderpool

14:40-14:55 **RUPERT SWIFT AWARD LECTURE: Pro-Inflammatory Epicardial Adipose Tissue as a Key Mediator of Right Ventricle Failure in Pulmonary Arterial Hypertension**  
Manon Mougín

14:55-15:20 What can omics teach us about the right ventricle?  
Soni-Savai Pullamsetti

15:20-15:45 What can we learn from the right ventricle in congenital heart disease?  
Beatrijs Bartelds

15:45-17:00 **Moderated poster discussion with refreshments, Robinson + Higgins Rooms**  
*Moderators: Deimante Hoppenot, Mona Lichtblau & Bradley Wertheim*

17:10-18:40 **Networking Reception, Breakout area**



Berlin, 2017

## SESSION 4: PH associated with lung diseases: hope or hype?

*Moderators: Gülfer Okumuş & Katarina Zeder*

08:00-08:25 KEYNOTE: Progress in PH in lung disease: hope or hype?  
Oksana Shlobin

08:25-08:50 Can animal models of PH in COPD deliver the breakthrough?  
Joan-Albert Barbera

08:50-09:05 Bidirectional crosstalk between sleep & PAH  
Yassine Sassi

09:05-09:30 What can bronchopulmonary dysplasia PH teach us about Group 3 PH  
Anne Hilgendorff

09:30-09:55 Rapid pro-con debate: Should we ever treat PH associated with COPD?  
PRO: Gabor Kovacs & CON: Katarina Zeder

09:55-10:25 Refreshment break, Breakout area

## SESSION 5: Global aspects of PH

*Moderators: Peter Leary, John Ryan & Zhenguo Zhai*

10:25-10:50 KEYNOTE: What is the real global burden of PH?  
John Feenstra

10:50-11:15 What can we learn from global PH registries?  
Athiththan Yogeswaran

11:15-11:30 The epidemiological & clinical burden of PAH in Latin America & the Caribbean:  
a systematic literature review  
Victoria Wurcel

11:30-11:55 Global burden of paediatric PH  
Mary Mullen

11:55-13:40 Lunch break, Breakout area

11:55-13:40 **Career Catalyst Luncheon**, Radisson Blu Royal Hotel Dublin Restaurant  
Host: Jason Weatherald

**Friday  
30 January**

Douglas Hyde  
(ground floor)

## SESSION 6: 20 years of progress in CTEPH

*Moderators: Sophia Anastasia Mouratoglou, Rehan Quadery & Patricia Thistlewaite*

13:40-14:05 KEYNOTE: BPA - techniques, outcomes & future directions  
Hiromi Matsubara

14:05-14:30 'Omics & CTEPH - are we going to see pathobiology advances changing management?  
Gustavo Heresi

14:30-14:45 Should we be treat CTEPD with no PH in the multimodal treatment era?  
Irene Lang

14:45-15:10 Rapid pro-con debate: In the era of multimodal therapy most patients should have their haemodynamics normalised  
PRO: Irene Lang & CON: Mark Toshner

15:10-16:15 Moderated poster discussion with refreshments

*Moderators: Katherine Bunclark, Prashant Bobhate, Chris Rhodes & Nayeli Zayas*

## SESSION 7: Translating innovation into PH therapies

*Moderators: Samar Farha, Andrea Olschewski & Laura Price*

16:15-16:40 KEYNOTE: Inflammation & PVD  
Speaker Lewis Rubin

16:40-17:05 DNA lesions & epigenetics: how we can translate complex repair mechanisms into practical applications  
Steeve Provencher

17:05-17:20 Oral abstract  
Speaker TBC

17:20-17:45 Carving new pathways: translating PDGFR $\beta$  or SGLT2 inhibition into PAH therapy  
Lisa Mielniczuk

19:30-00:30 Gala Dinner & Award Presentations, Guinness Storehouse



London, 2024

15 #PVRI2026

## SESSION 8: Precision medicine & artificial intelligence in PH

*Moderators: David Kiely, Shahin Moledina & Jason Weatherald*

08:00-08:25 KEYNOTE: The promise of AI  
Brad Maron

08:25-08:50 Precision medicine in PH: the emerging promise of molecular techniques  
Jane Leopold

08:50-09:15 Bioinformatic prediction of therapeutic targets in PH  
Corey Ventetuolo

09:15-09:30 AI-enabled digital stethoscope for screening congenital heart disease in children: a prospective pilot study  
Prashant Bobhate

09:30-09:55 AI-enhanced risk models for PH survival  
Andy Swift

09:55-11:00 Moderated poster discussion with refreshments

*Moderators: Colin Church, Brian McCullagh, Esther Nossent & Anita Saxena*

## SESSION 9: SHARKS DEN - new targets, biomarkers & devices in PH

*Moderators: Anna Hemnes, Abdullah M. Al-Dalaan, Werner Seeger, Edda Spiekerkoetter, Corey Ventetuolo & Martin Wilkins*

11:00-12:00 Pitch 1: Integrins in PH: sentinels of disease or keys to therapy?  
Sarah-Eve Lemay

Pitch 2: A rodent retirement plan: are human ex vivo models ready to take over?  
Chanil Valasarajan

Pitch 3: Plasma proteomics in PH: ready to outperform BNP for patient stratification?  
Woodcock Chen-Shan (Julia)

Pitch 4: Wearables in PH: complement or challenger to right-heart catheterisation?  
Jim White

12:00-13:45 Lunch break, Breakout area

12:00-13:45 Women in PH Luncheon, Radisson Blu Royal Hotel Dublin Restaurant  
Hosts: TBC

**SESSION 10: Innovative concepts for future thinking in PH**

A joint session with PVRI & PHA USA

*Moderators: Cihangir Kaymaz, Namita Sood & John Wort*

13:45-14:10 KEYNOTE: From remission to cure: lessons from cancer treatment for PH  
Raymond Benza

14:10-14:35 Beyond the heart and lung: inter-organ cross-talks in PH  
Kurt Prins

14:35-15:00 Muscle-lung cross talk in PH: a future therapeutic target?  
Charly Lai



15:00-15:30 Refreshment break

**SESSION 11: The future hope of living life to the full with PH**

*Moderators: Evan Brittain, Patricia George & Merve Keles*

15:30-15:50 Living with PH: life in harmony with research & innovation  
Alex Rothman

15:50-16:10 Modifying lifestyle to live life to the full with PH  
Ciara McCormack

16:10-16:30 KEYNOTE: The next 20 years in PH - what can we expect for our patients?  
Paul Hassoun

16:30-16:35 Meeting close



Rio de Janeiro, 2025

## PAH-ICON

ROOM: Robinson 1+2  
(1st floor)

### 6th Symposium of the International Consortium for Genetic Studies in P(A)H

#### Session 1

*Moderators: TBC*

- |             |  |
|-------------|--|
| 08:00-08:10 | Welcome & introduction<br>Micheala Aldred & Stefan Gräf  |
| 08:10-08:55 | Keynote I: 25 years BMPR2: past, present & future of PAH genetics<br>Richard Trembath  |
| 08:55-09:10 | Genomic determinants of therapy response in pulmonary veno-occlusive disease: insights from whole-genome sequencing & GWAS<br>Natalia Gallego-Zazo |
| 09:10-09:25 | Detection of CNVs through whole genome sequencing in patients with PAH<br>Monica Mora  |
| 09:25-09:35 | Discussion<br>All  |

---

09:35-09:50 Refreshment break, Breakout area

---

#### Session 2

*Moderators: TBC*

- |             |   |
|-------------|---|
| 09:50-10:35 | Keynote II: The role of mutations in epigenetic regulator genes in inflammation & PAH<br>Stephen Archer |
| 10:35-10:50 | Transcriptomic signatures of pulmonary vascular remodeling in COPD<br>Vasile Foris                      |
| 10:50-11:05 | DNA methylation signature in PAH, a potential molecular diagnostic tool<br>Jair Tenorio                 |
| 11:05-11:15 | Discussion<br>All   |

---

11:15-11:30 Refreshment break, Breakout area

---

#### Session 3

*Moderators: TBC*

- |             |  |
|-------------|--|
| 11:30-11:45 | SOX17 enhancer variant reduces endothelial progenitor cells in patients with PAH<br>James Klinger                      |
| 11:45-12:30 | Keynote III: TBX4life – the role model of a global, international patient initiative & research network<br>Eric Austin |
| 12:30-12:55 | Panel discussion, Q&A, networking & brainstorming<br>All   |
| 12:55-13:00 | Closing remarks<br>Micheala Aldred & Stefan Gräf   |

# Bookable functions

## **Friday, 30 January, Career Catalyst Luncheon**

Radisson Blu Royal Hotel Dublin Restaurant

Following the resounding success of our free PVRI Career Catalyst Luncheon in Rio last year, we're bringing this dynamic speed mentoring event to Dublin! Designed for early-career PH professionals and trainees, this luncheon offers unique micro-mentoring sessions with established, globally renowned PH researchers in an informal, welcoming setting. It's the perfect opportunity to expand your network, exchange ideas, and gain valuable career insights—all in one afternoon.

## **Friday, 30 January, Gala Dinner & Awards Presentation Evening**

Guinness Storehouse

Celebrate 20 years of PH innovation at this iconic venue with colleagues from around the world over fine food, drinks, and live entertainment. Your ticket also includes an immersive self-guided tour of interactive exhibits showcasing the brewing process, advertising history, and the story of Arthur Guinness. Tickets are priced at \$100/€88/£75 per person. Early career professionals and trainees can purchase a ticket for the discounted rate of \$88/€75/£65. Congress attendees may also purchase one guest ticket at full price to share this special night — places are limited, so secure your tickets early!

### **PVRI 2026 Awards include**

- PVRI Lifetime Achievement Award
- PVRI Achievement Award
- Special Recognition Awards
- The Butrous Foundation Award
- The Rupert Swift Award
- PVRI Abstract Awards

## **Saturday, 31 January, Women in PH Luncheon**

Radisson Blu Royal Hotel Dublin Restaurant

Now in its third year, the free Women in PH Luncheon continues to be a cornerstone of our congress. Originally founded to support educational opportunities for women in PH and strengthen their professional networks, this event celebrates inclusivity, diversity, and collaboration. Our mission is to unite and amplify women's voices, while fostering a supportive environment for all—men are warmly welcome to attend too.



Guangzhou, 2015



PVRI 2026 Dublin – Celebrating 20 Years of Progress & Innovation, 28 January – 1 February 2026, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **18 European CME credits (ECMEC®s)**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at <https://edhub.ama-assn.org/pages/applications>.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.



The European Board for Accreditation in Pneumology (EBAP) has granted PVRI 2026 Dublin with **28.5 CME credits, plus an additional 3 CME credits as a Mark of Excellence** in recognition of it being an exceptional event. The total EBAP credits delegates can claim is 31.5.

PVRI 2026 Dublin has EFPIA CVS approval, ref EMT-25-04671



[www.discoverireland.ie](http://www.discoverireland.ie)

# See you in Dublin!



[pvrinstitute.org](http://pvrinstitute.org)

The PVRI is a Charity registered in England and Wales (No. 1127115) and a Company limited by guarantee (No. 05780068).